HRP20170785T1 - Kombinacija anti-ctla4 antitijela sa etopozidom za sinergističko liječenje proliferativnih bolesti - Google Patents

Kombinacija anti-ctla4 antitijela sa etopozidom za sinergističko liječenje proliferativnih bolesti Download PDF

Info

Publication number
HRP20170785T1
HRP20170785T1 HRP20170785TT HRP20170785T HRP20170785T1 HR P20170785 T1 HRP20170785 T1 HR P20170785T1 HR P20170785T T HRP20170785T T HR P20170785TT HR P20170785 T HRP20170785 T HR P20170785T HR P20170785 T1 HRP20170785 T1 HR P20170785T1
Authority
HR
Croatia
Prior art keywords
demethylpipodophyllotoxin
ethylidene
pharmaceutically acceptable
solvate
hydrate
Prior art date
Application number
HRP20170785TT
Other languages
English (en)
Inventor
Francis Y. Lee
Maria Jure-Kunkel
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/462,168 external-priority patent/US8119129B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20170785T1 publication Critical patent/HRP20170785T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Claims (16)

1. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu u metodi za liječenje raka, koji sadrži administriranje kod sisavaca kod koga postoji potreba za sinergističko, terapijski efikasnom količinom anti-CTLA-4 antitijela sa 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegove farmaceutski prihvatljive soli, solvata, ili hidrata.
2. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje je anti-CTLA-4 antitijelo odabrano iz grupe koja se sastoji od ipilimumaba i tremelimumaba.
3. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje anti-CTLA-4 antitijelo je ipilimumab.
4. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, gdje je navedeni rak solidni tumor.
5. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 4, gdje je navedeni solidni tumor odabran iz grupe koja se sastoji od: raka pluća, sarkoma, fibrosarkoma, raka gušterače, raka prostate, i raka debelog crijeva.
6. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, gdje navedena metoda je za liječenje tumora koji je otporan na 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegovu farmaceutski prihvatljivu sol, solvat, ili hidrat.
7. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, gdje 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat je administriran prije administriranja navedenog anti-CTLA4 antitijela.
8. Anti--CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 7, gdje 4'-Demetilpipodofilotoksin 9-[4-,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat je administriran suštinski istovremeno sa administriranjem navedenog anti-CTLA4 antitijela.
9. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranazid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, gdje navedeno liječenje raka dalje sadrži anti-proliferativni citotoksični agens ili sam ili u kombinaciji sa radioterapijom.
10. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 9, gdje navedeni anti-proliferativni citotoksični agens je cisplatin.
11. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 9, gdje navedeni anti-proliferativni agens je karboplatin.
12. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 11, gdje 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat je administriran u dozi od oko 50 mg.
13. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-gluekopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 12, gdje 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat je administiriran putem intravenske infuzije kao sterilni liofil u jednodoznim bočicama koje sadrže etopozid fosfat ekvivalentan 100 mg etopozida, 32.7 mg natrijum citrata USP, i 300 mg dekstrana 40.
14. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 13, gdje navedeni anti-CTLA4 je administriran otprilike svaka tri tjedna.
15. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 14, gdje je rak sitnostanični rak pluća.
16. Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden--D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 15, gdje 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-β-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat je administriran u oko 50 mg do oko 900 mg po danu, poželjno oko 100 mg dnevno.
HRP20170785TT 2009-07-20 2017-05-26 Kombinacija anti-ctla4 antitijela sa etopozidom za sinergističko liječenje proliferativnih bolesti HRP20170785T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22691009P 2009-07-20 2009-07-20
US12/462,168 US8119129B2 (en) 2008-08-01 2009-07-30 Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
PCT/US2009/052209 WO2010014784A2 (en) 2008-08-01 2009-07-30 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP14162613.5A EP2769737B1 (en) 2009-07-20 2009-10-29 Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
HRP20170785T1 true HRP20170785T1 (hr) 2017-08-11

Family

ID=43499324

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170785TT HRP20170785T1 (hr) 2009-07-20 2017-05-26 Kombinacija anti-ctla4 antitijela sa etopozidom za sinergističko liječenje proliferativnih bolesti

Country Status (16)

Country Link
EP (4) EP3659596A1 (hr)
JP (3) JP5589077B2 (hr)
KR (1) KR101733255B1 (hr)
CN (1) CN102822200A (hr)
AU (1) AU2009350151B2 (hr)
CY (1) CY1119128T1 (hr)
DK (1) DK2769737T3 (hr)
ES (2) ES2768990T3 (hr)
HR (1) HRP20170785T1 (hr)
HU (1) HUE033312T2 (hr)
LT (1) LT2769737T (hr)
MX (1) MX2012000851A (hr)
PL (1) PL2769737T3 (hr)
PT (1) PT2769737T (hr)
SI (1) SI2769737T1 (hr)
WO (1) WO2011011027A1 (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
TWI686405B (zh) 2008-12-09 2020-03-01 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
KR20140038382A (ko) * 2011-03-10 2014-03-28 프로벡투스 파마슈티컬스 인코포레이티드 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제
WO2013022991A2 (en) 2011-08-08 2013-02-14 Curelab Oncology, Inc. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
CN110448566A (zh) * 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
US20150283237A1 (en) * 2014-04-02 2015-10-08 Mitchell S. Felder Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
WO2016040892A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies
EP3200775B1 (en) * 2014-10-03 2019-11-20 Novartis AG Combination therapies
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP6649941B2 (ja) * 2015-02-16 2020-02-19 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
AU2016229810A1 (en) * 2015-03-11 2017-09-14 Providence Health & Services-Oregon Compositions and methods for enhancing the efficacy of cancer therapy
JP6900323B2 (ja) * 2015-05-29 2021-07-07 アジェナス インコーポレイテッド 抗ｃｔｌａ−４抗体およびその使用方法
EP3313888A1 (en) * 2015-06-25 2018-05-02 Advanced Accelerator Applications Method of treatment of neuroendocrine tumors that over-express somatostatatin receptors
CN108367070B (zh) * 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
US11612653B2 (en) * 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
WO2017144543A1 (en) * 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
CN105560247B (zh) * 2016-03-04 2018-08-31 四川美大康华康药业有限公司 一种达沙替尼组合物片剂及其制备方法
CN109689056A (zh) * 2016-08-01 2019-04-26 亚尼塔公司 用于治疗癌症的组合
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018160536A1 (en) 2017-02-28 2018-09-07 Bristol-Myers Squibb Company Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
CN106943380B (zh) * 2017-05-17 2021-02-05 杜楠 Vegf单抗联合纳米紫杉醇在制备治疗癌性腹腔粘连药物中的应用
JP2020525019A (ja) * 2017-06-27 2020-08-27 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 白血病におけるｃｔｌａ４アンタゴニストに対する耐性を同定および治療するための組成物および方法
JP7365694B2 (ja) * 2017-06-29 2023-10-20 信夫 塚本 抗腫瘍免疫療法増強剤
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
JPWO2022004760A1 (hr) 2020-06-30 2022-01-06

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5120805A (en) 1991-06-05 1992-06-09 The Dow Chemical Company Reactor with surface agitator for solution polymerization process
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
AU691820B2 (en) 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
SI0892789T2 (sl) 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6277381B1 (en) 1997-03-21 2001-08-21 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
ES2209831T3 (es) 1999-02-22 2004-07-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilonas modificadas en c-21.
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
JP2003503354A (ja) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
EP1226136B1 (en) 1999-10-19 2004-12-29 Merck & Co., Inc. Tyrosine kinase inhibitors
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003512353A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
ES2215494T5 (es) 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
DE60208792T2 (de) 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005529873A (ja) * 2002-04-12 2005-10-06 メダレックス インコーポレイテッド Ｃｔｌａ−４抗体を使用した治療の方法
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004015130A2 (en) 2002-08-07 2004-02-19 Exelixis Modulators of rabggt and methods of use thereof
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
US7465446B2 (en) * 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
US20050051208A1 (en) 2003-06-17 2005-03-10 Mount Robert L. System for transferring heat in a thermoelectric generator system
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR100845354B1 (ko) * 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
AU2005300315A1 (en) * 2004-11-04 2006-05-11 Pfizer Products Inc. CTLA-4 antibody and aromatase inhibitor or combination treatment for breast cancer
NZ561138A (en) * 2005-03-23 2009-06-26 Pfizer Prod Inc Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
AU2006269555A1 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CN101325971A (zh) * 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP2008066402A (ja) 2006-09-05 2008-03-21 Fujifilm Corp 撮像素子および撮像装置
WO2008115404A1 (en) * 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US8449886B2 (en) * 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases

Also Published As

Publication number Publication date
LT2769737T (lt) 2017-06-26
EP2769737A1 (en) 2014-08-27
PL2769737T3 (pl) 2017-08-31
AU2009350151A1 (en) 2012-02-09
CY1119128T1 (el) 2018-02-14
KR101733255B1 (ko) 2017-05-08
AU2009350151B2 (en) 2015-07-16
JP5589077B2 (ja) 2014-09-10
SI2769737T1 (sl) 2017-06-30
EP3659596A1 (en) 2020-06-03
EP2947098A1 (en) 2015-11-25
EP2947098B1 (en) 2019-11-20
ES2629167T3 (es) 2017-08-07
EP2456790A1 (en) 2012-05-30
JP2014198737A (ja) 2014-10-23
CN102822200A (zh) 2012-12-12
PT2769737T (pt) 2017-06-29
EP2769737B1 (en) 2017-04-05
HUE033312T2 (en) 2017-11-28
ES2768990T3 (es) 2020-06-24
WO2011011027A1 (en) 2011-01-27
DK2769737T3 (en) 2017-07-24
JP2014167029A (ja) 2014-09-11
JP2012533619A (ja) 2012-12-27
JP5957036B2 (ja) 2016-07-27
MX2012000851A (es) 2012-06-08
JP5957043B2 (ja) 2016-07-27
KR20120048564A (ko) 2012-05-15

Similar Documents

Publication Publication Date Title
HRP20170785T1 (hr) Kombinacija anti-ctla4 antitijela sa etopozidom za sinergističko liječenje proliferativnih bolesti
Dilda et al. Arsenical-based cancer drugs
Hotte et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study
ES2668272T3 (es) Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación
EP2786756B1 (en) Combination therapy with a topoisomerase inhibitor
US20220265592A1 (en) Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
JP2020055884A (ja) がんのためのグルフォスファミド組み合わせ療法
CA2955384A1 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CA3087628A1 (en) Synergistic cancer treatment
Hillman et al. Axitinib improves radiotherapy in murine xenograft lung tumors
Chen et al. The antipancreatic cancer activity of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2
Berghmans et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
KR20180125967A (ko) 암 치료용 pic 포함 조성물
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
AU2009220942B2 (en) Methods of treatment employing prolonged continuous infusion of Belinostat
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
Zhang et al. The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma
KR101925553B1 (ko) Pi3-키나제 저해제 및 독소루비신의 복합조성물을 포함하는 항암용 약학조성물 및 이의 제조방법
Sohn et al. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
CA3135916A1 (en) Combined use of a-nor-5a androstane compound drug and anticancer drug
JP2004523518A (ja) より効能が大きく副作用の少ない癌治療方法
Shibamori et al. Rebamipide does not interfere with the antitumor effect of radiotherapy or chemotherapy in human oral tumor-bearing nude mice
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
RU2776995C2 (ru) Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью
US20220071982A1 (en) Methods and uses for treating cancer